Join us on World Diabetes Day, November 14th at 08:30 CET in Brussels, for our upcoming panel discussion in collaboration with Eli Lilly and Company.
The European pharmaceutical landscape is facing significant challenges, with the decline in R&D investments and a notable reduction in the global share of clinical trials since 2018. At the same time, China has tripled its R&D investment, intensifying global competition. These trends emphasise the urgency of the European Commission's proposed revision of general pharmaceutical legislation (GPL) aimed at enhancing patient access and sustaining Europe's competitiveness in the medical innovation sector.
A number of concerns revolve around the proposed GPL revisions. This revision is a critical part of the effort to improve patient access to high-quality medicines, however, it has raised widespread concerns regarding the reduction in regulatory data protection and the introduction of complex recovery targets. These issues have the potential to deter R&D investment in Europe, with potential ramifications for the future of medical innovation across the continent.
- Billy Kelleher, MEP, European Parliament.
- Elisabeth Dupont, European Regional Manager, International Diabetes Federation.
- David Talbot, Associate Vice President International Government, Eli Lilly.
- Additional TBC.